CVS three-lens brief
Evidence-based stock research on CVS. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Outperforming SPY by 21.1pp over 30 days. · Trading at 99% of its 52-week range — near the top of the band.
- Trading at 99% of its 52-week range — near the top of the band.
- RSI at 80 — technically overbought.
- Outperforming SPY by 21.1pp over 30 days.
- Debt-to-equity of 100.9 — balance-sheet-heavy.
CVS closed at $96.57 (+1.49%) as of 2026-05-13. Market cap: $123.22B. P/E (trailing) 42.4. Positives: outperforming SPY by 21.1pp over 30 days.. Concerns: trading at 99% of its 52-week range — near the top of the band.; rSI at 80 — technically overbought.. Last quarter: Revenue $100.43B, net income $2.94B, free cash flow $5.20B.
Why three lenses on CVS, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CVSacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CVS" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CVS brief"></iframe>